Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Charité - Universitätsmedizin Berlin, Germany.
Vaccine. 2012 Jun 22;30(30):4445-52. doi: 10.1016/j.vaccine.2012.04.081. Epub 2012 May 5.
A(H1N1)v2009 influenza vaccination of pregnant women was a challenge for health care providers, as little safety data were available.
We prospectively followed the pregnancies of women who were vaccinated at any time during pregnancy or ≤ 4 weeks prior to conception and compared these outcomes to a control cohort matched by the estimated date of birth. Primary endpoints: rate of spontaneous abortion and major malformations. Secondary endpoints: preeclampsia, gestational age at birth, and birth weight.
Pregnancy outcome of 323 women immunized with adjuvanted or non-adjuvanted A(H1N1)v2009 influenza vaccines from 2009-09-28 to 2010-03-31 were compared to 1329 control subjects. The risk for spontaneous abortions (HR 0.89; 95% CI 0.36-2.19) and the rate of major malformations (all trimesters: OR 0.87; 95% CI 0.38-1.77; preconception and first trimester exposure: OR 0.79; 95% CI 0.13-2.64) did not vary between the two cohorts. Furthermore, there was no increase in preeclampsia, prematurity, and intrauterine growth retardation in the vaccinated cohort.
The results of our study do not indicate a risk for the pregnant woman and the developing embryo/fetus after H1N1 vaccination. We provide and apply methods novel in observational studies on pregnancy outcome, especially if a single dose exposure is investigated.
对于医疗保健提供者来说,对孕妇进行 A(H1N1)v2009 流感疫苗接种是一个挑战,因为几乎没有安全性数据。
我们前瞻性地随访了在妊娠期间的任何时间或受孕前≤4 周内接种疫苗的孕妇的妊娠情况,并将这些结果与按估计出生日期匹配的对照组进行比较。主要终点:自然流产率和主要畸形率。次要终点:子痫前期、出生时的胎龄和出生体重。
2009 年 9 月 28 日至 2010 年 3 月 31 日期间,对 323 名接受佐剂或非佐剂 A(H1N1)v2009 流感疫苗免疫的孕妇的妊娠结局与 1329 名对照受试者进行了比较。自然流产的风险(HR 0.89;95%CI 0.36-2.19)和主要畸形的发生率(所有妊娠:OR 0.87;95%CI 0.38-1.77;受孕前和妊娠早期接触:OR 0.79;95%CI 0.13-2.64)在两个队列之间没有差异。此外,接种疫苗的队列中没有子痫前期、早产和宫内发育迟缓的发生率增加。
我们的研究结果表明,H1N1 疫苗接种后,孕妇和发育中的胚胎/胎儿没有风险。我们提供并应用了在妊娠结局观察性研究中新颖的方法,特别是如果研究单次剂量暴露的情况。